Sector News

AbbVie adding 100 jobs as part of $139M oncology expansion in Ireland

January 22, 2018
Life sciences

CEO Richard Gonzalez has made it clear he expects new oncology drugs to fill the yawning revenue gap AbbVie will experience with the loss of Humira patent protection. The company is prepping for that day with a $139 million expansion at a plant in Ireland where it will add 100 jobs.

An AbbVie spokesperson confirmed today that the drugmaker will invest €113.6 million ($139 million) in a sterile manufacturing expansion at the site in Sligo, Ireland, that will be used to produce cancer drugs. The drugmaker, which will get some financial assistance from the government, intends to add 100 jobs over the next three years.

AbbVie has expanded the Sligo sites several times in recent years, including a $115 million expansion announced in 2014 for producing its oral hep C drugs, another area it moved into as Humira’s patent losses drew nearer.

Humira remains the world’s best-selling drug with more than $16 billion in global sales, and AbbVie continues to defend it doggedly. The drugmaker, in fact, inked a patent settlement with Amgen last fall that will delay that company’s biosimilar until 2023.

But investors know eventually the copies will come, so AbbVie has been picking up oncology assets in recent years to prepare. It has a partnership with Roche for expected blockbuster Venclexta, a targeted blood cancer drug that’s approved for a rare form of leukemia. If it wins an expanded use, then it is expected to hit $1.5 billion to $2 billion in sales by the end of the decade and to grow to $3 billion by 2022, putting it among the top-selling cancer meds that year. But that is still a small part of Humira’s sales and so Gonzalez has promised more.

“Oncology will be a major growth driver for AbbVie over the next 10 years and beyond, further diversifying our business,” he said during the company’s third-quarter earnings call.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend